BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roberti R, Iannone LF, Palleria C, De Sarro C, Spagnuolo R, Barbieri MA, Vero A, Manti A, Pisana V, Fries W, Trifirò G, Naturale MD, Larussa T, De Francesco AE, Bosco V, Donato di Paola E, Citraro R, Luzza F, Bennardo L, Rodinò S, Doldo P, Spina E, Russo E, De Sarro G. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin 2020;36:1457-63. [PMID: 32573307 DOI: 10.1080/03007995.2020.1786681] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Larussa T, Abenavoli L, Fabiano G, Mancuso MA, Polimeni N, Dumitrascu DL, Luzza F. Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed. Minerva Gastroenterol 2021;67. [DOI: 10.23736/s2724-5985.21.02907-7] [Reference Citation Analysis]
2 Spagnuolo R, Abenavoli L, Larussa T, Iannelli C, Pellicano R, Fagoonee S, Doldo P, Luzza F. Safety profile of intravenous iron in inflammatory bowel disease: an up-to-date overview. Minerva Gastroenterol (Torino) 2022;68:111-8. [PMID: 33267572 DOI: 10.23736/S2724-5985.20.02819-6] [Reference Citation Analysis]
3 Candelli M, Franza L, Pignataro G, Ojetti V, Covino M, Piccioni A, Gasbarrini A, Franceschi F. Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:6242. [PMID: 34200555 DOI: 10.3390/ijms22126242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 d’Apolito M, Spagnuolo R, Siciliano MA, Barbieri V, Cosco C, Fiorillo L, Cuomo O, Zuccalà V, Correale P, Pensabene L, Rossi M, Doldo P, Tassone P, Tagliaferri P. Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report. Therapeutic Advances in Chronic Disease 2022;13:204062232110630. [DOI: 10.1177/20406223211063024] [Reference Citation Analysis]
5 Wellens J, Vermeire S, Sabino J. Let Food Be Thy Medicine-Its Role in Crohn's Disease. Nutrients 2021;13:832. [PMID: 33802429 DOI: 10.3390/nu13030832] [Reference Citation Analysis]
6 Picchianti-Diamanti A, Spinelli FR, Rosado MM, Conti F, Laganà B. Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases. Int J Mol Sci 2021;22:2638. [PMID: 33807944 DOI: 10.3390/ijms22052638] [Reference Citation Analysis]
7 Larussa T, Basile A, Palleria C, Iannelli C, Vero A, Giubilei L, De Sarro C, Suraci E, Marasco R, Imeneo M, Russo E, Abenavoli L, De Sarro G, Luzza F. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. Med Pharm Rep 2021;94:289-97. [PMID: 34430850 DOI: 10.15386/mpr-1897] [Reference Citation Analysis]
8 Uzzan S, Azab AN. Anti-TNF-α Compounds as a Treatment for Depression. Molecules 2021;26:2368. [PMID: 33921721 DOI: 10.3390/molecules26082368] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Nijakowski K, Rutkowski R, Eder P, Simon M, Korybalska K, Witowski J, Surdacka A. Potential Salivary Markers for Differential Diagnosis of Crohn's Disease and Ulcerative Colitis. Life (Basel) 2021;11:943. [PMID: 34575091 DOI: 10.3390/life11090943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Araujo DV, Muniz TP, Yang A, Keshavarzi S, Sorotsky H, Butler MO, Saibil S, Spreafico A, Hogg D. Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. Curr Oncol 2021;28:2173-9. [PMID: 34208089 DOI: 10.3390/curroncol28030201] [Reference Citation Analysis]
11 Yoshioka M, Sawada Y, Nakamura M. Diagnostic Tools and Biomarkers for Severe Drug Eruptions. Int J Mol Sci 2021;22:7527. [PMID: 34299145 DOI: 10.3390/ijms22147527] [Reference Citation Analysis]
12 Fedor I, Zold E, Barta Z. Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease. J Clin Med 2021;10:5984. [PMID: 34945280 DOI: 10.3390/jcm10245984] [Reference Citation Analysis]
13 Machado-Alba JE, Jiménez-Morales AL, Moran-Yela YC, Parrado-Fajardo IY, Valladales-Restrepo LF. Adverse drug reactions associated with the use of biological agents. PLoS One 2020;15:e0240276. [PMID: 33338057 DOI: 10.1371/journal.pone.0240276] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Pękala A, Filip R. Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn's Disease and Ulcerative Colitis-A Prospective Polish Population Study. J Clin Med 2021;10:5311. [PMID: 34830598 DOI: 10.3390/jcm10225311] [Reference Citation Analysis]
15 Sochal M, Fichna J, Gabryelska A, Talar-Wojnarowska R, Białasiewicz P, Małecka-Wojciesko E. Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy. J Clin Med 2021;10:4615. [PMID: 34640632 DOI: 10.3390/jcm10194615] [Reference Citation Analysis]
16 Dastoli S, Nisticò SP, Morrone P, Patruno C, Leo A, Citraro R, Gallelli L, Russo E, De Sarro G, Bennardo L. Colchicine in Managing Skin Conditions: A Systematic Review. Pharmaceutics 2022;14:294. [DOI: 10.3390/pharmaceutics14020294] [Reference Citation Analysis]
17 Lu W, Deng Y, Fang Z, Zhai Q, Cui S, Zhao J, Chen W, Zhang H. Potential Role of Probiotics in Ameliorating Psoriasis by Modulating Gut Microbiota in Imiquimod-Induced Psoriasis-Like Mice. Nutrients 2021;13:2010. [PMID: 34207960 DOI: 10.3390/nu13062010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Hagan M, Hayee BH, Rodriguez-Mateos A. (Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review. Molecules 2021;26:1843. [PMID: 33805938 DOI: 10.3390/molecules26071843] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Cucinotta U, Romano C, Dipasquale V. Diet and Nutrition in Pediatric Inflammatory Bowel Diseases. Nutrients 2021;13:655. [PMID: 33671453 DOI: 10.3390/nu13020655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Amoruso GF, Nisticò SP, Iannone L, Russo E, Rago G, Patruno C, Bennardo L. Ixekizumab May Improve Renal Function in Psoriasis. Healthcare (Basel) 2021;9:543. [PMID: 34066917 DOI: 10.3390/healthcare9050543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
21 Lopez-Santalla M, Garin MI. Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases. Biomedicines 2021;9:1507. [PMID: 34829736 DOI: 10.3390/biomedicines9111507] [Reference Citation Analysis]
22 Iannone LF, Bennardo L, Palleria C, Roberti R, De Sarro C, Naturale MD, Dastoli S, Donato L, Manti A, Valenti G, D'Amico D, D'Attola S, De Francesco AE, Bosco V, Donato Di Paola E, Nisticò SP, Citraro R, Russo E, De Sarro G. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS One 2020;15:e0241575. [PMID: 33141869 DOI: 10.1371/journal.pone.0241575] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
23 Suri K, Bubier JA, Wiles MV, Shultz LD, Amiji MM, Hosur V. Role of MicroRNA in Inflammatory Bowel Disease: Clinical Evidence and the Development of Preclinical Animal Models. Cells 2021;10:2204. [PMID: 34571853 DOI: 10.3390/cells10092204] [Reference Citation Analysis]